CytoDyn Inc. appointed Robert E. Hoffman as its new CEO, effective October 20, 2026, replacing Dr. Jacob Lalezari who will remain as Head of Research. Hoffman, previously CFO, brings extensive biotech leadership experience and will guide CytoDyn through its next phase of clinical development focused on advancing its oncology drug leronlimab. The leadership change aims to support clinical results, regulatory milestones, and strategic partnerships as the company moves forward in cancer treatment innovation.
CytoDyn's CEO appointment is noted here with Pluang's Health sector market data as of Oct 20, 2026 03:02 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 87 rose and 62 fell today. Notable movers include MESO at USD 11.96 with a -9.98% change, BNGO at USD 1.25 down -8.76%, and IBRX at USD 8.46 down -7.84%, with IBRX showing a Pluang order activity of 33% Sell / 67% Buy and a typical hold time of 2 days.
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
